Key takeaways
- GHK is a tripeptide the body produces naturally, and its blood levels drop substantially with age, from roughly 200 ng/mL at age 20 to about 80 ng/mL by age 60.
- GHK binds copper to form GHK-Cu, and review research describes how this complex can influence the expression of thousands of human genes tied to wound healing, anti-inflammatory pathways, and DNA repair.
- Most of the published evidence comes from reviews, laboratory skin models, and gene-expression studies, with controlled human trials only now beginning.
- A Phase 2 wound-healing trial of topical GHK-Cu gel is currently recruiting, testing whether it speeds re-epithelialization of standardized skin wounds against a placebo gel.
- GHK-Cu is most studied in skin remodeling and tissue regeneration, where its effects on collagen, antioxidant activity, and matrix balance are best characterized.
What is GHK-Cu?
GHK-Cu is a small copper-binding peptide. Its core, GHK, is a tripeptide made of three amino acids (glycine, histidine, and lysine) that occurs naturally in the human body and binds copper with high affinity to form the complex written as GHK-Cu.
One reason GHK has attracted research interest is that its levels appear to decline notably with age. According to a 2015 review in BioMed Research International, circulating GHK falls from roughly 200 ng/mL around age 20 to about 80 ng/mL by age 60. Because this decline coincides with reduced regenerative capacity in skin and other tissues, researchers have asked whether restoring GHK might support some of the body's repair processes. That question is still being explored rather than settled.
How it is thought to work
The most striking findings about GHK come from gene-expression research. A 2018 review in the International Journal of Molecular Sciences reported that GHK-Cu can modulate the activity of around 4,000 human genes, including those involved in wound healing, anti-inflammatory responses, and DNA repair. Rather than acting on a single target, GHK appears to nudge a broad network of pathways toward a more regenerative state.
In the skin specifically, GHK has been described as helping to balance collagen production and matrix metalloproteinase (MMP) activity, the enzymes that break down the skin's structural proteins. A 2020 review in Aging Pathobiology and Therapeutics also points to antioxidant and skin-remodeling properties. These are proposed and observed mechanisms drawn from laboratory and animal work, and they describe how GHK-Cu may act rather than a guaranteed clinical result.
From lab models to the first human trial
The evidence base for GHK-Cu is built largely from review articles, laboratory work, and mechanism studies, so it leans toward preclinical research rather than large human trials.
On the laboratory side, a 2023 study in the Journal of Cosmetic Dermatology examined GHK-Cu combined with hyaluronic acid in a skin model and found upregulation of collagen IV, a marker associated with skin regeneration. This is an in vitro finding, observed in a controlled lab system rather than in living people. On the mechanistic side, a 2017 paper in Brain Sciences looked at GHK and gene expression patterns relevant to the nervous system and cognitive decline, again at the gene level rather than as a tested treatment.
That picture is now moving toward controlled human testing. A Phase 2 trial registered as NCT07437586 (the CuHeal study), sponsored by Hudson Biotech and currently recruiting, is testing a topical GHK-Cu gel in a split-wound design: each participant receives two standardized skin wounds, one treated with GHK-Cu gel and the other with a matching placebo gel, with healing tracked over three weeks and scar quality assessed at twelve. It is designed to measure directly whether GHK-Cu speeds wound re-epithelialization in people, the kind of question earlier laboratory studies could only suggest. Results from a trial like CuHeal will show how well the mechanistic findings translate into clinical outcomes.
What it is being explored for
The clearest research focus for GHK-Cu is skin: its role in collagen and MMP balance, antioxidant activity, and tissue remodeling. Broader interest in wound healing, anti-inflammatory effects, and DNA repair follows from the gene-modulation findings, and a smaller body of mechanism work has touched on the nervous system.
People who find GHK-Cu interesting are often those thinking about skin quality and the regenerative changes that come with aging. GHK-Cu has a rich mechanistic and laboratory record, with the first controlled human wound-healing trial now underway. Whether it is appropriate for any individual is a clinical question, not a general one, and depends on a person's health context and goals, which is why these decisions are made with a qualified physician after a full assessment.
The evidence
Selected references, each verified against primary sources (PubMed and ClinicalTrials.gov). Explore the full, filterable research library on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. GHK-Cu is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.